학술논문
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years -- PROTECT Cohort, July 2021-February 2022.
Document Type
Article
Author
Fowlkes, Ashley L.; Yoon, Sarang K.; Lutrick, Karen; Gwynn, Lisa; Burns, Joy; Grant, Lauren; Phillips, Andrew L.; Ellingson, Katherine; Ferraris, Maria V.; LeClair, Lindsay B.; Mathenge, Clare; Yoo, Young M.; Thiese, Matthew S.; Gerald, Lynn B.; Solle, Natasha Schaefer; Jeddy, Zuha; Odame-Bamfo, Leah; Mak, Josephine; Hegmann, Kurt T.; Gerald, Joe K.
Source
Subject
*COVID-19 vaccines
*GENETIC variation
*VACCINE effectiveness
*MESSENGER RNA
*SYMPTOMS
*COVID-19 testing
*COVID-19 pandemic
*EVALUATION
*CHILDREN
*
*
*
*
*
*
*
*
Language
ISSN
0149-2195
Abstract
The article reports on the results of the Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT) cohort study on the effectiveness of 2-dose BNT162b2 messenger RNA (mRNA) vaccine from Pfizer-BioNTech in preventing SARS-CoV-2 infection among children 5-11 years old and adolescents aged 12-15 years. Also cited is the conduct of reverse transcription-polymerase chain reaction testing and viral whole genome sequencing.